Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.

abstract：:Pregnancy may be complicated by new onset or preexisting asthma. This article reviews the recognition and management of asthma during pregnancy, as well as general principles of asthma medication use during pregnancy. ...

journal_title：Therapeutic advances in respiratory disease

authors： Namazy JA,Schatz M

更新日期：2014-08-01 00:00:00

abstract：:One of the great challenges of lung transplantation is to bridge the dichotomy between supply and demand of donor organs so that the maximum number of potential recipients achieve a meaningful benefit in improvements in survival and quality of life. To achieve this laudable goal is predicated on choosing candidates wh...

journal_title：Therapeutic advances in respiratory disease

authors： Mitchell AB,Glanville AR

更新日期：2019-01-01 00:00:00

abstract：OBJECTIVE:Severe exacerbations in alpha-1-antitrypsin (AAT)-deficient patients with chronic obstructive pulmonary disease (COPD) and/or emphysema are a major cause of hospitalization. A multicentre, observational, retrospective study was undertaken to evaluate the effect of continuous AAT augmentation therapy in reduci...

journal_title：Therapeutic advances in respiratory disease

authors： Barros-Tizón JC,Torres ML,Blanco I,Martínez MT,Investigators of the rEXA study group.

更新日期：2012-04-01 00:00:00

abstract：:Fluoroquinolones are commonly used to treat lung infections in patients with cystic fibrosis. These patients are susceptible to lung infection with common bacteria such as Staphylococcus aureus and Haemophilus influenzae, but are also prone to infection by opportunistic bacteria, including Pseudomonas aeruginosa. The ...

journal_title：Therapeutic advances in respiratory disease

authors： Hurley M,Smyth A

更新日期：2012-12-01 00:00:00

abstract：:Immunotherapy has significantly altered the treatment landscape for many cancers, including non-small cell lung cancer (NSCLC). Currently approved immuno-oncology agents for lung cancer are aimed at the reversal of immune checkpoints, programmed death protein-1 (PD-1) and programmed death ligand-1 (PD-L1). Although re...

journal_title：Therapeutic advances in respiratory disease

authors： Villanueva N,Bazhenova L

更新日期：2018-01-01 00:00:00

abstract：:The use of biomarkers on pleural fluid (PF) specimens may assist the decision-making process and enhance clinical diagnostic pathways. Three paradigmatic examples are heart failure, tuberculosis and, particularly, malignancy. An elevated PF concentration of the amino-terminal fragment of probrain natriuretic peptide (...

journal_title：Therapeutic advances in respiratory disease

authors： Porcel JM

更新日期：2018-01-01 00:00:00

abstract：OBJECTIVE:To identify potential predictors for invasive and non-invasive mechanical ventilation in coronavirus disease 2019 (COVID-19) patients. METHODS:This study retrospectively analyzes data of 516 patients with confirmed COVID-19, who were categorized into three groups based on which mechanical ventilation method ...

journal_title：Therapeutic advances in respiratory disease

authors： Li W,Lin F,Dai M,Chen L,Han D,Cui Y,Pan P

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:Autologous blood is a novel, high-efficacy sclerosant for treatment of malignant pleural effusion (MPE), similar to tetracycline. There has been no comparative data between autologous blood and a worldwide sclerosant like talc. We aimed to compare the effectiveness of autologous blood versus talc pleurodesis...

journal_title：Therapeutic advances in respiratory disease

authors： Keeratichananont W,Kaewdech A,Keeratichananont S

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) therapy has been approved for sepsis-associated acute respiratory distress syndrome, but its efficacy for other rapidly progressive interstitial pneumonias (RPIPs) is unclear. The purpose of this study was to examine the efficacy of PM...

journal_title：Therapeutic advances in respiratory disease

authors： Ichiyasu H,Horio Y,Masunaga A,Migiyama Y,Sakamoto Y,Jodai T,Ideguchi H,Okabayashi H,Hamada S,Yoshida C,Hirosako S,Okamoto S,Kohrogi H

更新日期：2017-07-01 00:00:00

abstract：:In recent years in the management of pulmonary arterial hypertension (PAH), endothelin receptor antagonists (ERAs) represent a well-established class of therapeutic agents with clear beneficial effects. Macitentan (Opsumit®), a dual ERA optimized for efficacy and safety, is the newest drug in the class. Macitentan pre...

journal_title：Therapeutic advances in respiratory disease

authors： Steriade A,Seferian A,Jaïs X,Savale L,Jutant EM,Parent F,Sitbon O,Humbert M,Simonneau G,Montani D

更新日期：2014-06-01 00:00:00

abstract：:The issue of electronic cigarettes is one of the most controversial topics in public health. There is intense debate and dividing opinions about their use patterns, health effects and association with smoking. This is expected since they were only recently introduced to the market and they refer to a harm-reduction ap...

journal_title：Therapeutic advances in respiratory disease

authors： Farsalinos K

更新日期：2018-01-01 00:00:00

abstract：:Avoidance of allergens in the treatment of asthma has hitherto not achieved significant benefit despite the strong evidence that allergy both increases severity and contributes to exacerbations of asthma. House dust mite, cat and dog allergens are the most common perennial allergic triggers and most avoidance strategi...

journal_title：Therapeutic advances in respiratory disease

authors： Warner JO

更新日期：2017-04-01 00:00:00

abstract：:Asthma is one of the most common respiratory disorders in clinical practice, affecting up to 13% of people worldwide. Inflammation is the most important component of asthma and inhaled corticosteroids (ICS) are recommended as the first line controller treatment for patients of all ages. Treatment with corticosteroids ...

journal_title：Therapeutic advances in respiratory disease

authors： del Giudice MM,Pezzulo A,Capristo C,Alterio E,Caggiano S,de Benedictis D,Capristo AF

更新日期：2009-10-01 00:00:00

abstract：BACKGROUND:Central airway obstruction (CAO) is a serious condition that affects patients with both benign and malignant diseases. Timely recognition of CAO is crucial for prompt intervention aimed at improving the symptoms and quality of life of these patients. The aim of this study is to evaluate the formal radiology ...

journal_title：Therapeutic advances in respiratory disease

authors： Harris K,Alraiyes AH,Attwood K,Modi K,Dhillon SS

更新日期：2016-04-01 00:00:00

abstract：OBJECTIVES:To describe the health-related quality of life (HRQL) in a cohort of COPD patients recruited in primary care and identify the variables of the patients and the treatment associated with impaired HRQL. METHOD:Multicenter, observational study of patients with COPD recruited in Primary Care centers. Data regar...

journal_title：Therapeutic advances in respiratory disease

authors： Miravitlles M,Molina J,Naberan K,Cots JM,Ros F,Llor C,EVOCA study.

更新日期：2007-12-01 00:00:00

abstract：:Clinical and immunologic tolerance are hallmarks of successful allergen immunotherapy (AIT). Clinical benefits such as reduced symptoms, pharmacotherapy intake and improvement of quality of life persist following cessation of treatment. Successful AIT is associated with suppression of allergic inflammatory cells such ...

journal_title：Therapeutic advances in respiratory disease

authors： Kappen JH,Durham SR,Veen HI,Shamji MH

更新日期：2017-01-01 00:00:00

abstract：INTRODUCTION:Since its introduction to the market in 2016, selexipag has been an alternative oral therapy among both treatment-naïve patients and those with mono or dual therapy failure; however, limited information is available regarding the presentation and management of patients with pulmonary arterial hypertension ...

journal_title：Therapeutic advances in respiratory disease

authors： Highland KB,Hull M,Pruett J,Elliott C,Tsang Y,Drake W

更新日期：2019-01-01 00:00:00

abstract：:Pulmonary arterial hypertension (PAH) is a chronic condition of elevated pulmonary arterial pressures with associated increases in pulmonary vascular resistance leading to right ventricular failure, which was almost uniformly fatal prior to the introduction of pulmonary hypertension specific therapy. Systemic prostacy...

journal_title：Therapeutic advances in respiratory disease

authors： Stream AR,Bull TM

更新日期：2012-10-01 00:00:00

abstract：:There is evidence of aberrations in the vitamin D-endocrine system in subjects with respiratory diseases. Vitamin D deficiency is highly prevalent in patients with respiratory diseases, and patients who receive vitamin D have significantly larger improvements in inspiratory muscle strength and maximal oxygen uptake. S...

journal_title：Therapeutic advances in respiratory disease

authors： Luong KV,Nguyen LT

更新日期：2013-12-01 00:00:00

abstract：OBJECTIVE:The ultra-short course preseasonal allergy vaccine, containing the adjuvant monophosphoryl lipid A (MPL), is effective in treating allergic symptoms; however, the efficacy in controlling asthmatics symptoms has not been fully demonstrated. We aimed at evaluating whether the ultra-short preseasonal course of i...

journal_title：Therapeutic advances in respiratory disease

authors： Scichilone N,Scalici V,Arrigo R,Bellia V

更新日期：2013-08-01 00:00:00

abstract：OBJECTIVES:Both autofluorescence imaging bronchoscopy and narrow-band imaging have shown promise in the detection of premalignant airway lesions, each by utilizing different bandwidths of lights for better characterization of the mucosal and submucosal vascular grid. Since previously published meta-analyses have shown ...

journal_title：Therapeutic advances in respiratory disease

authors： Iftikhar IH,Musani AI

更新日期：2015-10-01 00:00:00

abstract：BACKGROUND:Pseudomonas aeruginosa (Pa) is the predominant pulmonary pathogen in patients with cystic fibrosis (CF). Tobramycin nebulization is used for the eradication of Pa infection. Nowadays, tobramycin dry powder inhalation (DPI) is available as well. This study reports the results of eradicating Pa with tobramycin...

journal_title：Therapeutic advances in respiratory disease

authors： Akkerman-Nijland AM,Yousofi M,Rottier BL,Van der Vaart H,Burgerhof JGM,Frijlink HW,Touw DJ,Koppelman GH,Akkerman OW

更新日期：2020-01-01 00:00:00

abstract：:As our understanding of the pathobiology and natural history of the various forms of interstitial lung disease (ILD) has evolved, so have our approaches to treating this heterogeneous group of lung disorders. The earliest pharmacologic agents used to treat various forms of ILD were corticosteroids, and corticosteroids...

journal_title：Therapeutic advances in respiratory disease

authors： Kim R,Meyer KC

更新日期：2008-10-01 00:00:00

abstract：:COPD may be characterized by significant changes in airway mucosal blood vessels, which may contribute to bronchial airway remodeling. The airway wall is more vascularized in COPD patients than in healthy subjects, though this phenomenon is less evident than in asthmatic patients. The vascular mucosal changes in the a...

journal_title：Therapeutic advances in respiratory disease

authors： Zanini A,Chetta A,Olivieri D

更新日期：2008-06-01 00:00:00

abstract：OBJECTIVES:Pharmacologically mediated bronchodilation is important in the management of asthma, and is primarily achieved with β₂-agonists. Novel compounds should preferably have a longer duration of action and a better systemic side effect profile than established alternatives at comparable peak bronchodilation. This ...

journal_title：Therapeutic advances in respiratory disease

authors： Bjermer L,Rosenborg J,Bengtsson T,Lötvall J

更新日期：2013-10-01 00:00:00

abstract：:Angiogenesis is a driving force of a tumor's development. Targeting this process is an attractive option, as this is a feature shared by most of the solid tumors. A lot of antiangiogenic drugs have been developed following this path, including bevacizumab, sorafenib, sunitinib, vandetanib, ramucirumab, motesanib and m...

journal_title：Therapeutic advances in respiratory disease

authors： Caglevic C,Grassi M,Raez L,Listi A,Giallombardo M,Bustamante E,Gil-Bazo I,Rolfo C

更新日期：2015-08-01 00:00:00

abstract：:To investigate whether dry powder inhalers (DPIs) function in a constrained situation, a literature analysis was performed to evaluate the use of DPIs compared with established therapies in the treatment of acute asthma and COPD, irrespective of rapid-acting beta(2)-agonist used. The external databases Medline, Embase...

journal_title：Therapeutic advances in respiratory disease

authors： Selroos O,Borgström L,Ingelf J

更新日期：2009-04-01 00:00:00

abstract：:Chronic obstructive pulmonary disease (COPD) is a chronic condition that negatively affects several patient-centered outcomes. Among these, exercise capacity, dyspnea, and quality of life are the most relevant. In this article, factors contributing to exercise limitation, increase in exercise-induced dyspnea, quality ...

journal_title：Therapeutic advances in respiratory disease

authors： de Blasio F,Polverino M

更新日期：2012-08-01 00:00:00

abstract：:Within telehealth there are a number of domains relevant to pulmonary care: telemonitoring, teleassistance, telerehabilitation, teleconsultation and second opinion calls. In the last decade, several studies focusing on the effects of various telemanagement programs for patients with chronic obstructive pulmonary disea...

journal_title：Therapeutic advances in respiratory disease

authors： Vitacca M,Montini A,Comini L

更新日期：2018-01-01 00:00:00

abstract：OBJECTIVES:This study evaluated the effectiveness of behavioral interventions (brief counseling, nonspecific psychological support in groups - NSGS and cognitive behavioral group therapy - CBGT) in combination with bupropion SR for smoking cessation in the field, through a smoking cessation clinic. METHODS:Two-hundred...

journal_title：Therapeutic advances in respiratory disease

authors： Rovina N,Nikoloutsou I,Katsani G,Dima E,Fransis K,Roussos C,Gratziou C

更新日期：2009-12-01 00:00:00